Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in
the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially …

Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …

Liver cancer is one of the most common malignancies, with severe morbidity and mortality.
While considerable progress has been made in liver cancer treatment, the 5-year overall …

Hepatocellular carcinoma (HCC) is one of the common and fatal malignancies, which is a
significant global health problem. The clinical applicability of traditional surgery and other …

Abstract Background This open-label, Phase 1b/2 study evaluated the highly selective MET
inhibitor tepotinib in systemic anticancer treatment (SACT)-naive Asian patients with …

Simple Summary MET is a receptor tyrosine kinase encoded by the MET proto-oncogene
that has a significant role in cancer cell progression. Several drugs targeting MET are under …

Hepatocellular carcinoma (HCC) remains one of the most common malignancies and the
third cause of cancer-related death worldwide, with surgery being the best prognostic tool …

Simple Summary Around 3% of patients with Non-Small-Cell Lung Cancer (NSCLC)
harbour a MET exon 14 skipping mutation (METex14). Early mutation identification is …

Simple Summary The MET gene encodes a receptor critical for cell growth and repair. It
plays diverse roles in processes like organ development, wound healing, and blood vessel …

Hepatocellular carcinoma (HCC) is the most common primary liver cancer whose incidence
continues to rise in many parts of the world due to a concomitant rise in many associated risk …